Pierian Biosciences, the team behind the DiaTech project, have announced that their three poster abstracts have been accepted for presentation at the 2019 meeting of the American Association for Cancer Research (AACR) on March 29th till April 3rd at The Georgia World Congress Centre, Atlanta, Georgia.
There were two submissions for ChemoINTEL and one submission for ImmunoINTEL (ImmunoINTEL already presenting at ASCO-SITC meeting), these are the two diagnostic platforms that make up DiaTech.
The following posters will be presented:
ChemoINTEL Poster Title – ChemoINTEL: A high-throughput, multi-parametric compound screening platform for intelligent lead compound and therapeutic combination identification.
ChemoINTEL Poster Title – ChemoINTEL: A multi-parametric assay of chemotherapeutic responses in isolated primary tumour cells.
ImmunoINTEL Poster Title – Automated flow cytometric analysis of tumour heterogeneity, immunophenotypic and functional profiles, and co-expression of checkpoint receptors in the context of tumour aneuploidy.
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. Having all three submissions accepted for presentations at this prestigious meeting is a huge boost for the project. This demonstrates the level of interest in the DiaTech ChemoINTEL and ImmunoINTEL diagnostic platforms from the international scientific community.